Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy

被引:178
作者
Kupelian, PA
Elshaikh, M
Reddy, CA
Zippe, C
Klein, EA
机构
[1] Cleveland Clin Fdn, Dept Radiat Oncol, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Urol, Cleveland, OH 44195 USA
关键词
D O I
10.1200/JCO.2002.01.150
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To review biochemical relapse-free survival (bRFS) rates after either external-beam radiotherapy (RT) or radical prostatectomy (RP) for localized Prostate cancer. Patients and Methods: All 1,682 patients had pretreatment prostate-specific antigen (PSA) levels and biopsy Gleason scores (bGS) assigned. No adjuvant therapy was administered after local treatment. RP was the treatment in 1,054 patients (63%) and RT in 628 patients (37%). Median follow-up was 51 months (range, 1 to 134). The median follow-up for RIP versus RT patients was 50.5 v 51.0 months. Biochemical relapse was considered detectable PSA levels (> 0.2 ng/mL) in RP patients and three consecutive rising PSA levels in RT patients. The analysis was repeated with a more stringent definition of biochemical control after either RP or RT-namely, reaching and maintaining a PSA level less than or equal to 0.5 ng/mL-and excluding patients receiving any androgen deprivation (AD). Results: Eight-year bRFS rates for RIP versus RT were 72% and 70%, respectively (P = .010). Multivariate analysis indicated T stage (P < .001), pretreatment PSA (P < .001), bGS (P < .001), year of therapy (P < .001), and neoadjuvant AD (P = .019) to be the only independent predictors of relapse. Age (P = .78), race (P = .29), prior transurethral resection of prostate (P = .81), and treatment modality (P = .96) were not independent predictors of treatment failure. Fifty-one percent of RP patients had favorable tumors (T1 to T2A, pretreatment PSA less than or equal to 10 ng/mL, bGS less than or equal to 7), compared with only 34% of RT patients (P < .001). Repeat analysis with a stringent definition of biochemical failure and excluding patients receiving AD indicated no impact of treatment modality on outcome. Conclusion: Eight-year biochemical failure rates were identical between RT and RP in any subgroup. Outcome is determined mainly by pretreatment PSA levels, bGS, clinical T stage, and, for RT patients, radiation dose. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:3376 / 3385
页数:10
相关论文
共 31 条
[11]   Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration [J].
Jhaveri, FM ;
Klein, EA ;
Kupelian, PA ;
Zippe, C ;
Levin, HS .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3167-3172
[12]   Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer [J].
Kattan, MW ;
Zelefsky, MJ ;
Kupelian, PA ;
Scardino, PT ;
Fuks, Z ;
Leibel, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) :3352-3359
[13]   Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy [J].
Klein, EA ;
Kupelian, PA ;
Tuason, L ;
Levin, HS .
UROLOGY, 1998, 51 (05) :766-773
[14]  
Kupelian P, 1997, CANCER J SCI AM, V3, P78
[15]   Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era [J].
Kupelian, PA ;
Buchsbaum, JC ;
Patel, C ;
Elshaikh, M ;
Reddy, CA ;
Zippe, C ;
Klein, EA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (03) :704-711
[16]   Higher than standard radiation doses (≥72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer [J].
Kupelian, PA ;
Mohan, DS ;
Lyons, J ;
Klein, EA ;
Reddy, CA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (03) :567-574
[17]   Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: A novel analysis [J].
Leibman, BD ;
Dillioglugil, O ;
Scardino, PT ;
Abbas, F ;
Rogers, E ;
Wolfinger, RD ;
Kattan, MW .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2267-2271
[18]   Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate [J].
Lyons, JA ;
Kupellan, PA ;
Mohan, DS ;
Reddy, CA ;
Klein, EA .
UROLOGY, 2000, 55 (01) :85-90
[19]  
Martinez AA, 2000, CANCER-AM CANCER SOC, V88, P425, DOI 10.1002/(SICI)1097-0142(20000115)88:2<425::AID-CNCR25>3.0.CO
[20]  
2-Z